Medroxyprogesterone acetate (MPA) in advanced granulosa cell tumours of the ovary--a new therapeutic approach?

por Malik, S. T., Slevin, M. L.
Publicado 1991

Treatment decisions in advanced ovarian cancer.

por Cody, M. M., Slevin, M. L.
Publicado 1989

The use of erythropoietin in a Jehovah's Witness undergoing major surgery and chemotherapy.

por Johnson, P. W., King, R., Slevin, M. L., White, H.
Publicado 1991

Using mathematical models to estimate drug resistance and treatment efficacy via CT scan measurements of tumour volume.

por Gregory, W. M., Reznek, R. H., Hallett, M., Slevin, M. L.
Publicado 1990

Lack of effect of interferon alpha 2a upon fluorouracil pharmacokinetics.

por Seymour, M. T., Patel, N., Johnston, A., Joel, S. P., Slevin, M. L.
Publicado 1994

Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen

por Slater, S, Shamash, J, Wilson, P, Gallagher, C J, Slevin, M L
Publicado 2002

A study to investigate the incidence of early satiety in patients with advanced cancer.

por Armes, P. J., Plant, H. J., Allbright, A., Silverstone, T., Slevin, M. L.
Publicado 1992

Who should measure quality of life, the doctor or the patient?

por Slevin, M. L., Plant, H., Lynch, D., Drinkwater, J., Gregory, W. M.
Publicado 1988

The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide.

por Harvey, V. J., Slevin, M. L., Joel, S. P., Johnston, A., Wrigley, P. F.
Publicado 1985

Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.

por Seymour, M. T., Johnson, P. W., Hall, M. R., Wrigley, P. F., Slevin, M. L.
Publicado 1994

Geographical epidemiology of ovarian and testicular germ cell cancers.

por Kamdar, R. H., Oliver, R. T., Othieno-Abinya, N., Gallagher, C. J., Slevin, M. L.
Publicado 1998

Demonstration of hepatic steatosis by computerized tomography in patients receiving 5-fluorouracil-based therapy for advanced colorectal cancer.

por Peppercorn, P. D., Reznek, R. H., Wilson, P., Slevin, M. L., Gupta, R. K.
Publicado 1998

The treatment of intraperitoneal malignant disease with monoclonal antibody guided 131I radiotherapy.

por Ward, B., Mather, S., Shepherd, J., Crowther, M., Hawkins, L., Britton, K., Slevin, M. L.
Publicado 1988

Phase II trial of UFT in advanced colorectal and gastric cancer.

por Malik, S. T., Talbot, D., Clarke, P. I., Osborne, R., Reznek, R., Wrigley, P. F., Slevin, M. L.
Publicado 1990

Oral urea in the treatment of secondary tumours in the liver.

por Clark, P. I., Slevin, M. L., Webb, J. A., Osborne, R. J., Jones, S., Wrigley, P. F.
Publicado 1988

Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule.

por Osborne, R. J., Malik, S. T., Slevin, M. L., Harvey, V. J., Spona, J., Salzer, H., Williams, C. J.
Publicado 1988

Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer.

por Lee, C. R., Nicholson, P. W., Souhami, R. L., Slevin, M. L., Hall, M. R., Deshmukh, A. A.
Publicado 1993

Tumour markers for prediction of survival and monitoring of remission in small cell lung cancer.

por Johnson, P. W., Joel, S. P., Love, S., Butcher, M., Pandian, M. R., Squires, L., Wrigley, P. F., Slevin, M. L.
Publicado 1993

An analysis of first-time enquirers to the CancerBACUP information service: variations with cancer site, demographic status and geographical location

por Boudioni, M, McPherson, K, Mossman, J, Boulton, M, Jones, A L, King, J, Wilson, E, Slevin, M L
Publicado 1999

Explanation at the opioid receptor level for differing toxicity of morphine and morphine 6-glucuronide.

por Hucks, D., Thompson, P. I., McLoughlin, L., Joel, S. P., Patel, N., Grossman, A., Rees, L. H., Slevin, M. L.
Publicado 1992